Search results | Regeneron Pharmaceuticals


Partnering Agreements with Regeneron Pharmaceuticals

The Partnering Agreements with Regeneron Pharmaceuticals report provides an in-depth insight into the partnering interests and activites of one of the worlds leading biopharma companies.


Regeneron Pharmaceuticals : Right technology, right time

Regeneron Pharmaceuticals is Biopharmaceutical Company focusing on the development of human antibody technologies for the treatment of a number of different diseases.

Regeneron Pharmaceuticals: Partnering activity 2009-2014

Regeneron Pharmaceuticals announced around 18 partnering / licensing deals since 2009.

Regeneron Pharmaceuticals: Company profile

Cubist Pharmaceuticals – Shaping developments in antibiotics

Cubist Pharmaceuticals is a biopharmaceutical company developing and commercializing medications for acute care in hospitals and surgical environments.

Dealtalk: Sanofi could acquire L’Oreal’s stake, buy more of Regeneron

According to dealtalk, repurchasing L’Oreal’s 9 percent stake in Sanofi might make sense for the French drugmaker if the $12 billion holding is put up for sale.

Biomarin Pharmaceuticals: Company profile

Ophthalmics partnering – recent deals analysis 2009-2014

Deal analysis by Current Agreements  shows that ophthalmics dealmaking activity has been steady with an average of 68 deals signed since 2009.

Current Agreements Deal Analysis Update : June 2014

This month we provide you with an overview of life science deal making activity, covering partnering, M&A and financing in May 2014.

Dendreon: Cutting costs, increasing profitability

Seattle based biotechnology Company Dendreon discovers and develops therapies for patients suffering with cancer.

Biopharma features strongly in 2013 world’s most innovative companies list

Partnering activity of the biopharma companies in Forbes Most Innovative Company list reviewed


Sorry, your search returned no results.


Sanofi acquires undisclosed common stock from Regeneron Pharmaceuticals

Sanofi intends to acquire Common Stock of Regeneron through open market purchases and direct purchases from shareholders.

Regeneron Pharmaceuticals converts interleukin-1 antibody opt-in rights to royalty agreement with Novartis

Under the first royalty agreement, Regeneron is entitled to receive royalties on worldwide sales of Novartis’ canakinumab (ACZ885), a fully human anti-interleukin-IL1β antibody currently under regulatory review to treat cryopyrin-associated periodic syndrome (CAPS) and in development for a number of other inflammatory diseases. On the basis of the same agreement Regeneron waives its rights to more »

Sanofi invests $71 million in Regeneron through equity financing

Sanofi has invested $71 million in Regeneron Pharmaceutical,  raising its stake in Regeneron Pharmaceuticals to 22.5 percent.

Regeneron and Avalanche sign Pharma alliance for $640 million

Regeneron Pharmaceuticals and Avalanche Biotechnologies announced the formation of a broad collaboration to discover, develop and commercialize novel gene therapy products for the treatment of ophthalmologic diseases.

Pharma alliance between Regeneron and Bayer to develop combination therapy

Regeneron Pharmaceuticals and Bayer Healthcare form a pharma alliance to co-develop a potential combination therapy for $65.5 million.

Biotech hunted become the new hunters as valuations soar

A short time ago, biotech companies were viewed as takeover targets, now they are more likely to be buyers as stock valuations soar on back of promising new drugs

Bayer and Santen enter co-promotion agreement for Eylea injection in Japan

Santen Pharmaceuticals negotiated copromotion rights to Regeneron Pharmaceuticals and Bayer HealthCare’s Eylea (aflibercept; VEGF Trap-Eye) injection in Japan